New pain drug shows promise in small tummy tuck study
NCT ID NCT04182880
First seen Apr 20, 2026 · Last updated Jun 19, 2026 · Updated 12 times
Summary
This Phase 2a study tested an experimental drug called CPL-01 in 20 people who had mini-abdominoplasty (a type of tummy tuck). The goal was to see if the drug is safe and how it behaves in the body after surgery. Participants received either CPL-01 or a placebo, and researchers measured drug levels in the blood over several days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABDOMINOPLASTY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chesapeake Research Group
Pasadena, Maryland, 21122, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CPL-01 (an experimental painkiller)
What this could lead to
If it works, this could lead to a new option for managing pain after surgery with fewer side effects.
What could go wrong
This is a small, early-phase study (20 people) focused on safety and drug levels, not on how well it works. The results may not apply to larger groups or other surgeries.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.